Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540946 | 0.94 | POLB (0.54) | TDP1SRCCES1ALDH1A1CA1 | |
| SCHEMBL350056 | 0.90 | TSHR (0.53) | TDP1CES1ALDH1A1CA1CA2 | |
| SCHEMBL9055248 | 0.89 | MAPT (0.53) | TDP1CES1ALDH1A1CA1CA2 | |
| SCHEMBL11214879 | 0.83 | TDP1 (0.55) | TDP1CES1ALDH1A1CA1CA2 | |
| SCHEMBL5632968 | 0.82 | MAPT (0.53) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL5156314 | 0.82 | MEN1 (0.62) | TDP1CES1ALDH1A1CA1CA2 | |
| SCHEMBL3889135 | 0.82 | MAPT (0.57) | TDP1CES1ALDH1A1CA1CA2 | |
| SCHEMBL10170602 | 0.82 | MEN1 (0.62) | TDP1CES1ALDH1A1CA1CA2 | |
| SCHEMBL3749117 | 0.82 | MEN1 (0.62) | TDP1CES1ALDH1A1CA1CA2 | |
| SCHEMBL6998064 | 0.81 | MEN1 (0.55) | TDP1CES1ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103703006-A | Hcv protease inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS CO LTD | 2014-04-02 | — | — | CN | disclosed |
| US-20130317034-A1 | COMBINATION THERAPY FOR TREATING DIABETES | JAPAN TOBACCO INC. (JP) | 2013-11-28 | — | — | US | disclosed |
| EP-2571352-A1 | SELECTIVE HDAC INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20120302636-A1 | METHOD OF TREATING A DISORDER ASSOCIATED WITH MTP | AKROS PHARMA INC. | 2012-11-29 | — | — | US | disclosed |
| WO-2012049566-A1 | COMBINATION THERAPY FOR USE IN TREATING DIABETES | JAPAN TOBACCO INC. (JP) | 2012-04-19 | — | — | WO | disclosed |
| WO-2011146855-A1 | SELECTIVE HDAC INHIBITORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2010148179-A1 | METHOD OF TREATING A DISORDER ASSOCIATED WITH MTP | JAPAN TOBACCO INC. (JP) | 2010-12-23 | — | — | WO | disclosed |
| US-7759366-B2 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-7012146-B2 | Ion channel modulating agents | POSEIDON PHARMACEUTICALS A/S (DK) | 2006-03-14 | — | — | US | disclosed |
| US-20020169203-A1 | Ion channel modulating agents | NEUROSEARCH A/S (DK) | 2002-11-14 | — | — | US | disclosed |
| EP-1140784-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037422-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-29 | — | — | WO | disclosed |
| US-5324648-A | Anticoagulants; antitumor agents | GEORGIA TECH RESEARCH CORPORATION (US) | 1994-06-28 | — | — | US | disclosed |
| US-5281721-A | Substituted carboxy- or carbonyl sulfide-containing 2-benzopyran or 2-benzothiopyran derivatives | GEORGIA TECH RESEARCH CORPORATION (US) | 1994-01-25 | — | — | US | disclosed |
| US-5109018-A | Emphysema therapy | GEORGIA TECH RESEARCH CORPORATION (US) | 1992-04-28 | — | — | US | disclosed |
| US-4954519-A | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents | GEORGIA TECH RESEARCH CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| US-4845242-A | ANTITUMOR | GEORGIA TECH RESEARCH CORPORATION (US) | 1989-07-04 | — | — | US | disclosed |
| US-4596822-A | Chromene or thiochromene ring containing enzyme inhibitor | GEORGIA TECH RESEARCH CORPORATION (US) | 1986-06-24 | — | — | US | disclosed |
| US-4273773-A | IN COMBINATION WITH A DIURETIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317034-A1 | COMBINATION THERAPY FOR TREATING DIABETES | DPP4, DPP7, DPP3 | TDP1 2369/4885SRC 2717/4885CES1 188/4885 |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | GPR119, GIPR, LIPC | TDP1 3400/4885SRC 2288/4885CES1 33/4885 |
| US-20120302636-A1 | METHOD OF TREATING A DISORDER ASSOCIATED WITH MTP | MTPN, APOB, HMGCR | TDP1 701/4885SRC 4268/4885CES1 222/4885 |
| US-20020169203-A1 | Ion channel modulating agents | KCNN3, KCNN1, KCNN2 | TDP1 4307/4885SRC 1618/4885CES1 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.